(redirected from Diovan hct)
Also found in: Dictionary, Thesaurus.
Related to Diovan hct: hydrochlorothiazide, valsartan


an angiotensin II antagonist used as an antihypertensive, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.



Pharmacologic class: Angiotensin II receptor antagonist

Therapeutic class: Antihypertensive

Pregnancy risk category C (first trimester), D (second and third trimesters)


Blocks the vasoconstrictive and aldosterone-producing effects of angiotensin II at various receptor sites, including vascular smooth muscle and adrenal glands


Tablets: 40 mg, 80 mg, 160 mg, 320 mg

Indications and dosages


Adults: Initially, 80 to 160 mg P.O. daily. May increase as needed to a maximum of 320 mg P.O. daily, or a diuretic may be added.

Children ages 6 to 16: Initially, 1.3 mg/kg (up to 40 mg total) P.O. once daily; dosage range is 1.3 to 2.7 mg/kg (40 to 160 mg total).

Heart failure

Adults: 40 mg P.O. b.i.d., titrated to 80 mg or 160 mg P.O. b.i.d., as tolerated

Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction

Adults: 20 mg P.O. b.i.d., followed by titration to 40 mg P.O. b.i.d., with subsequent titration to a target maintenance dosage of 160 mg P.O. b.i.d., as tolerated

Dosage adjustment

• Symptomatic hypotension

• Renal dysfunction

Off-label uses

• Left ventricular hypertrophy

• Diabetic nephropathy


• None


Use cautiously in:

• severe heart failure; volume or sodium depletion; hepatic or renal impairment; obstructive biliary disorders; angioedema; aortic, mitral valve, or renal artery stenosis; hyperkalemia, hypotension

• pregnant or breastfeeding patients

• children younger than age 6 (safety not established).


• Give with or without food.

• For children who can't swallow tablets or children for whom calculated dosage doesn't correspond to available tablet strength, use a suspension but be aware that exposure to the suspension is 1.6 times greater than the tablet.

• To prepare 160 ml of a 4-mg/ml suspension, add 80 ml of Ora-Plus to bottle containing eight valsartan 80-mg tablets and shake for at least 2 minutes. Allow suspension to stand for at least 1 hour. Then shake for at least 1 additional minute. Add 80 ml of Ora-Sweet to bottle and shake for at least 10 seconds before giving appropriate dose. May store suspension for 30 days at room temperature or up to 75 days if refrigerated.

Be aware that drug isn't recommended for children with glomerular filtration rate of less than 30 ml/minute/1.732.

Adverse reactions

CNS: dizziness, fatigue, headache

CV: hypotension, palpitations

EENT: sinus disorders, rhinitis, pharyngitis

GI: nausea, diarrhea, constipation, abdominal pain, dry mouth

GU: albuminuria, renal impairment

Hematologic: neutropenia

Metabolic: hyperkalemia

Musculoskeletal: back pain, joint pain, muscle cramps

Respiratory: cough, upper respiratory tract infection

Skin: alopecia, angioedema

Other: dental pain, fever, viral infection, edema


Drug-drug. Nonsteroidal anti-inflammatory drugs including selective cyclooxygenase-2 inhibitors: increased risk of renal impairment including acute renal failure in elderly patients, volume-depleted patients, or those with compromised renal function; loss of valsartan antihypertensive effect

Other antihypertensives: increased risk of hypotension

Potassium-sparing diuretics, potassium supplements: increased risk of hyperkalemia

Drug-diagnostic tests. Serum creatinine, serum and urine albumin, urine potassium: increased levels

Drug-food. Salt substitutes containing potassium: increased risk of hyperkalemia

Drug-herbs. Ephedra (ma huang): reduced hypotensive effect of valsartan

Drug-behaviors. Alcohol use: increased CNS depression

Patient monitoring

• Monitor blood pressure closely, especially during initial therapy and dosage adjustments.

• Assess potassium level. Stay alert for hyperkalemia.

• Be aware that in black patients, drug may be ineffective when used alone. Additional agents may be required.

Patient teaching

• Tell patient he may take with or without food.

• For children who can't swallow tablets or children for whom calculated dosage doesn't correspond to available tablet strength, show caregiver how to prepare a suspension.

Instruct female of childbearing age to report pregnancy immediately.

• Advise breastfeeding patient to avoid breastfeeding while taking drug.

• Advise patient to avoid potassium-containing salt substitutes.

• Caution patient to avoid alcohol.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, herbs, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


An angiotensin II receptor blocker drug, C24H29N5O3, used to treat hypertension and heart failure.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.


A drug that interferes with the action of ANGIOTENSIN II and is used to treat high blood pressure (HYPERTENSION). A brand name is Diovan.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
continues to market branded Diovan and Diovan HCT and is offering a $4 co-pay card program for those products.
Besides their availability through the co-pay card program to eligible patients, Diovan and Diovan HCT will continue to be offered through the Novartis Patient Assistance Foundation Inc.
Drug Company Expiry Month Sales ($ Bil.) Avapro BMS/Sanofi March 0.6 Viagra Pfizer March 1.0 Seroquel IR AstraZeneca March 3.1 Avandia GSK March 0.4 Geodon Pfizer March 0.9 Plavix BMS/Sanofi May 6.2 Tricor Abbott July 1.4 Actos Takeda/Eli Lilly August 3.5 Singulair Merck August 3.2 Diovan HCT Novartis September 2.5 Detrol Pfizer September 0.7 Enbrel Amgen/Pfizer November 3.3 Atacand AstraZeneca December 0.2 Sources: Food and Drug Administration, company filings, Fitch Ratings.
Generics Continue To Represent A Significant Opportunity In The Coming Years 2011 Liptor Zyprexa Levaquin Concerta Taxotere 20.1 2012 Plavix Seroquel Singulair Athos Lexapro Diovan Diovan HCT Eloxatin Geodon Tricor 145MG Provigil 35.9 2013 Cymbalta Oxycontln ER Niaspan Aciphex 10.9 2014 Nexium Capaxone Celebrex Novolog 16.6 2015 Ability Namenda Androgel Lovaza 12.7 Source: IMS Health, CVS Caremark estimates.